Nabeel Bardeesy
Overview
Explore the profile of Nabeel Bardeesy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
206
Citations
22962
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chaturantabut S, Oliver S, Frederick D, Kim J, Robinson F, Sinopoli A, et al.
J Clin Invest
. 2025 Feb;
PMID: 40014401
Translocations involving FGFR2 gene fusions are common in cholangiocarcinoma and predict response to FGFR kinase inhibitors. However, response rates and durability are limited due to the emergence of resistance, typically...
2.
Zhang Z, Liu Y, Luo Z, Wu M, Evans C, Qu Z, et al.
bioRxiv
. 2025 Feb;
PMID: 39975355
Mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are common in multiple types of human cancer, leading to the accumulation of D-2-hydroxyglutarate (D2HG) and the promotion of tumorigenesis. Here we...
3.
Sun Y, Maggs L, Panda A, Wright S, Cicerchia A, Jenney A, et al.
Cancer Immunol Res
. 2025 Jan;
13(2):210-228.
PMID: 39785827
Novel therapeutic strategies are needed to improve the efficacy of chimeric antigen receptor (CAR) T cells as a treatment of solid tumors. Multiple tumor microenvironmental factors are thought to contribute...
4.
Ellis H, Braconi C, Valle J, Bardeesy N
Am J Pathol
. 2024 Dec;
195(3):437-452.
PMID: 39730074
Cholangiocarcinoma is an aggressive bile duct malignancy with heterogeneous genomic features. Although most patients receive standard-of-care chemotherapy/immunotherapy, genomic changes that can be targeted with established or emerging therapeutics are common....
5.
Ying H, Kimmelman A, Bardeesy N, Kalluri R, Maitra A, DePinho R
Genes Dev
. 2024 Nov;
39(1-2):36-63.
PMID: 39510840
Pancreatic ductal adenocarcinoma (PDAC) poses a grim prognosis for patients. Recent multidisciplinary research efforts have provided critical insights into its genetics and tumor biology, creating the foundation for rational development...
6.
Cheng M, Chu A, Li Z, Yang S, Smith M, Zhang Q, et al.
JCI Insight
. 2024 Oct;
9(22).
PMID: 39388288
Immune evasion by tumors is promoted by low T cell infiltration, ineffective T cell activity directed against the tumor, and reduced tumor antigen presentation. The TET2 DNA dioxygenase gene is...
7.
Chaturantabut S, Oliver S, Frederick D, Kim J, Robinson F, Sinopoli A, et al.
bioRxiv
. 2024 Sep;
PMID: 39345400
Summary: We identify biparatopic FGFR2 antibodies that are effective against FGFR2 fusion driven cholangiocarcinoma.
8.
Gritti I, Wan J, Weeresekara V, Vaz J, Tarantino G, Bryde T, et al.
Cancer Discov
. 2024 Sep;
15(2):382-400.
PMID: 39326063
This work combines functional studies in model systems and examination of human tumor specimens to define a central oncogenic pathway driven by DNAJB1-PRKACA fusions in FLC. DNAJB1-PRKACA-mediated inactivation of the...
9.
Vijay V, Karisani N, Shi L, Hung Y, Vu P, Kattel P, et al.
bioRxiv
. 2024 Jul;
PMID: 39026794
Biliary tract cancers (BTCs) are a group of deadly malignancies encompassing intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. Here, we present the integrative analysis of 63 BTC cell...
10.
Wu M, Kondo H, Kammula A, Shi L, Xiao Y, Dhiab S, et al.
Science
. 2024 Jul;
385(6705):eadl6173.
PMID: 38991060
() is the most commonly mutated metabolic gene across human cancers. Mutant IDH1 (mIDH1) generates the oncometabolite (R)-2-hydroxyglutarate, disrupting enzymes involved in epigenetics and other processes. A hallmark of -mutant...